149 related articles for article (PubMed ID: 35656180)
1. 1,3,5-triazines inhibit osteosarcoma and avert lung metastasis in a patient-derived orthotopic xenograft mouse model with favorable pharmacokinetics.
Su Q; Xu B; Tian Z; Gong Z
Iran J Basic Med Sci; 2022 Mar; 25(3):295-301. PubMed ID: 35656180
[TBL] [Abstract][Full Text] [Related]
2. Novel 1,3,5-triazine-nicotinohydrazide derivatives induce cell arrest and apoptosis in osteosarcoma cancer cells and inhibit osteosarcoma in a patient-derived orthotopic xenograft mouse model.
Su Q; Xu B; Tian Z; Gong Z
Chem Biol Drug Des; 2022 Feb; 99(2):320-330. PubMed ID: 34811888
[TBL] [Abstract][Full Text] [Related]
3. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
4. Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents
Su Q; Xu B; Tian Z; Gong Z
Acta Pharm; 2022 Sep; 72(3):389-402. PubMed ID: 36651540
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
6. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
7. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
[TBL] [Abstract][Full Text] [Related]
8. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
[TBL] [Abstract][Full Text] [Related]
10. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
[TBL] [Abstract][Full Text] [Related]
11. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
[TBL] [Abstract][Full Text] [Related]
13. CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells.
Sun JY; Hou YJ; Yin YB; Wang FZ; Yang MF; Zhang YY; Fan CD; Sun BL
Biomed Pharmacother; 2020 Oct; 130():110544. PubMed ID: 32721630
[TBL] [Abstract][Full Text] [Related]
14. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
17. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
18. A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.
Igarashi K; Murakami T; Kawaguchi K; Kiyuna T; Miyake K; Zhang Y; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Tsuchiya H; Elliott I; Eilber FC; Hoffman RM
Oncotarget; 2017 Sep; 8(37):62111-62119. PubMed ID: 28977930
[TBL] [Abstract][Full Text] [Related]
19. Retraction of: A005, a novel inhibitor of phosphatidylinositol 3-kinase/mammalian target of rapamycin, prevents osteosarcoma-induced osteolysis.
Lian Z; Han J; Huang L; Wei C; Fan Y; Xu J; Zhou M; Feng H; Liu Q; Chen L; Li Z; Cheng H; Yuan G; Lin X; Song F; Su Y; Wang C; Huang G; Qin A; Song Y; Yao G
Carcinogenesis; 2019 Apr; 40(2):e1-e13. PubMed ID: 29635391
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
